LAVIPHARM S.A. NA EO 1 Market Cap ($269.79 Million)
Market Cap & Net Worth: LAVIPHARM S.A. NA EO 1 (BXA0)
LAVIPHARM S.A. NA EO 1 market cap. LAVIPHARM S.A. NA EO 1 (F:BXA0) has a market capitalization of $269.79 Million (€230.77 Million) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #15037 globally and #1487 in its home market, demonstrating a 3.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LAVIPHARM S.A. NA EO 1's stock price €1.45 by its total outstanding shares 169043561 (169.04 Million). Also see BXA0 operating cash flow for how efficiently the company converts equity into cash flow.
LAVIPHARM S.A. NA EO 1 Market Cap History (2022–2026)
LAVIPHARM S.A. NA EO 1 market cap history from 2022 to 2026. Data shows growth from $118.58 Million to $286.17 Million (18.34% CAGR). Check BXA0 share price today for real-time trading data and today's change.
LAVIPHARM S.A. NA EO 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LAVIPHARM S.A. NA EO 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LAVIPHARM S.A. NA EO 1 equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.66x
LAVIPHARM S.A. NA EO 1's market cap is 2.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.69x
LAVIPHARM S.A. NA EO 1's market cap is 15.69 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $118.58 Million | $39.06 Million | $834.00K | 3.04x | 142.18x |
| 2023 | $151.78 Million | $47.84 Million | $1.87 Million | 3.17x | 81.12x |
| 2024 | $140.91 Million | $52.95 Million | $8.98 Million | 2.66x | 15.69x |
Competitor Companies of BXA0 by Market Capitalization
Companies near LAVIPHARM S.A. NA EO 1 in the global market cap rankings as of November 1, 2026. Also see BXA0 total asset value for a full breakdown of the balance sheet.
Key companies related to LAVIPHARM S.A. NA EO 1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of LAVIPHARM S.A. NA EO 1 (2022–2026)
Market capitalization of LAVIPHARM S.A. NA EO 1 from 2022 to today. Between 2022 and today, LAVIPHARM S.A. NA EO 1's market cap moved from $118.58 Million to $ 286.17 Million, with a yearly change of 18.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €286.17 Million | +71.56% |
| 2025 | €166.80 Million | +18.37% |
| 2024 | €140.91 Million | -7.16% |
| 2023 | €151.78 Million | +28.00% |
| 2022 | €118.58 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of LAVIPHARM S.A. NA EO 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $269.79 Million USD |
| MoneyControl | $269.79 Million USD |
| MarketWatch | $269.79 Million USD |
| marketcap.company | $269.79 Million USD |
| Reuters | $269.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more